Exact Mass: 1064.5602099999999

Exact Mass Matches: 1064.5602099999999

Found 10 metabolites which its exact mass value is equals to given mass value 1064.5602099999999, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Pneumocandin B0

N-{6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,21,23,25-octahydroxy-3-[1-hydroxy-2-(C-hydroxycarbonimidoyl)ethyl]-15-(1-hydroxyethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0,]heptacosa-4,7,16,22-tetraen-18-yl}-10,12-dimethyltetradecanimidate

C50H80N8O17 (1064.5641150000001)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents > D054714 - Echinocandins Pneumocandin B0 (L-688786) is a synthetic intermediate of Cancidas.

   

PIP(22:3(10Z,13Z,16Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

{[(1R,3S)-3-({[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C52H90O18P2 (1064.5602099999999)


PIP(22:3(10Z,13Z,16Z)/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:3(10Z,13Z,16Z)/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of 10Z,13Z,16Z-docosenoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/22:3(10Z,13Z,16Z))

{[(1R,3S)-3-({[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(10Z,13Z,16Z)-tricosa-10,13,16-trienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C52H90O18P2 (1064.5602099999999)


PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/22:3(10Z,13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/22:3(10Z,13Z,16Z)), in particular, consists of one chain of 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 10Z,13Z,16Z-docosenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

Pneumocandin_B0

(10R,12S)-N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide

C50H80N8O17 (1064.5641150000001)


Pneumocandin B0 (L-688786) is a synthetic intermediate of Cancidas.

   

12-benzoyl-tayloron 3-O-beta-D-thevetopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-cymaropyranoside

12-benzoyl-tayloron 3-O-beta-D-thevetopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-digitoxopyranosyl-(1->4)-beta-D-cymaropyranoside

C55H84O20 (1064.5555664)


   

Pneumocandin B0

(10R,12S)-N-{(2R,6S,9S,11R,12R,14aS,15S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2,1-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide

C50H80N8O17 (1064.5641150000001)


An echinocandin initially isolated as a very minor bioactive fermentation product of Glarea lozoyensis (originally known as Zalerion arboricola). Subsequent random mutagenesis work and optimisation of the fermentation medium permitted the industrial production of pneumocandin B0, which is used as the starting point for the synthesis of the antifungal drug caspofungin. D000890 - Anti-Infective Agents > D000935 - Antifungal Agents > D054714 - Echinocandins Pneumocandin B0 (L-688786) is a synthetic intermediate of Cancidas.

   

PIP(22:3(10Z,13Z,16Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

PIP(22:3(10Z,13Z,16Z)/20:3(8Z,11Z,14Z)-2OH(5,6))

C52H90O18P2 (1064.5602099999999)


   

PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/22:3(10Z,13Z,16Z))

PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/22:3(10Z,13Z,16Z))

C52H90O18P2 (1064.5602099999999)


   

(10r,12s)-n-[(3s,6s,9s,11r,15s,18r,20r,21r,24s,25s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,21,23,25-octahydroxy-3-[(1r)-1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-15-[(1r)-1-hydroxyethyl]-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl]-10,12-dimethyltetradecanimidic acid

(10r,12s)-n-[(3s,6s,9s,11r,15s,18r,20r,21r,24s,25s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,21,23,25-octahydroxy-3-[(1r)-1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-15-[(1r)-1-hydroxyethyl]-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl]-10,12-dimethyltetradecanimidic acid

C50H80N8O17 (1064.5641150000001)


   

n-{6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,21,23,25-octahydroxy-3-[1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-15-(1-hydroxyethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl}-10,12-dimethyltetradecanimidic acid

n-{6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,11,17,20,21,23,25-octahydroxy-3-[1-hydroxy-2-(c-hydroxycarbonimidoyl)ethyl]-15-(1-hydroxyethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,22-tetraen-18-yl}-10,12-dimethyltetradecanimidic acid

C50H80N8O17 (1064.5641150000001)